Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.

Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, Lin HM, Aishah A, Varney B, Liu-Fu F, Lee LS, Nagarajan SR, Shearer RF, Hardie RA, Raftopulos NL, Kakani MS, Saunders DN, Holst J, Horvath LG, Butler LM, Hoy AJ.

Mol Cancer Res. 2019 Apr;17(4):949-962. doi: 10.1158/1541-7786.MCR-18-0347. Epub 2019 Jan 15.

PMID:
30647103
2.

Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.

Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE.

Eur Urol Oncol. 2018 Sep;1(4):325-337. doi: 10.1016/j.euo.2018.04.019. Epub 2018 Jun 6.

3.

A patient-derived explant (PDE) model of hormone-dependent cancer.

Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, Robinson JL, Schiewer MJ, Ma S, Kapur P, Sutherland PD, Hoffmann CE, Roehrborn CG, Gomella LG, Carroll JS, Birrell SN, Knudsen KE, Raj GV, Butler LM, Tilley WD.

Mol Oncol. 2018 Sep;12(9):1608-1622. doi: 10.1002/1878-0261.12354. Epub 2018 Aug 16.

4.

Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ, Butler LM.

Mol Cell Proteomics. 2018 Aug;17(8):1470-1486. doi: 10.1074/mcp.RA118.000633. Epub 2018 Apr 9.

5.

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Centenera MM, Selth LA, Ebrahimie E, Butler LM, Tilley WD.

Cold Spring Harb Perspect Med. 2018 Dec 3;8(12). pii: a030478. doi: 10.1101/cshperspect.a030478. Review.

PMID:
29530945
6.

Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.

Armstrong HK, Gillis JL, Johnson IRD, Nassar ZD, Moldovan M, Levrier C, Sadowski MC, Chin MY, Tomlinson Guns ES, Tarulli G, Lynn DJ, Brooks DA, Selth LA, Centenera MM, Butler LM.

Sci Rep. 2018 Feb 1;8(1):2090. doi: 10.1038/s41598-018-19871-4.

7.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
8.

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.

Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ.

Mol Cancer Ther. 2017 Dec;16(12):2689-2700. doi: 10.1158/1535-7163.MCT-17-0074. Epub 2017 Aug 11.

9.

A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.

Armstrong HK, Koay YC, Irani S, Das R, Nassar ZD; Australian Prostate Cancer BioResource, Selth LA, Centenera MM, McAlpine SR, Butler LM.

Prostate. 2016 Dec;76(16):1546-1559. doi: 10.1002/pros.23239. Epub 2016 Aug 16.

PMID:
27526951
10.

A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, Stylianou N, Sweeney K, Soekmadji C, Jovanovic L, Nelson CC, Zoubeidi A, Butler LM, Goodall GJ, Hollier BG, Gregory PA, Tilley WD.

Oncogene. 2017 Jan 5;36(1):24-34. doi: 10.1038/onc.2016.185. Epub 2016 Jun 6.

PMID:
27270433
11.

Androgen control of lipid metabolism in prostate cancer: novel insights and future applications.

Butler LM, Centenera MM, Swinnen JV.

Endocr Relat Cancer. 2016 May;23(5):R219-27. doi: 10.1530/ERC-15-0556. Epub 2016 Apr 29. Review.

PMID:
27130044
12.

Erratum to: IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.

Carter SL, Centenera MM, Tilley WD, Selth LA, Butler LM.

BMC Cancer. 2016 Mar 3;16:177. doi: 10.1186/s12885-016-2215-3. No abstract available.

14.

Maximizing the Therapeutic Potential of HSP90 Inhibitors.

Butler LM, Ferraldeschi R, Armstrong HK, Centenera MM, Workman P.

Mol Cancer Res. 2015 Nov;13(11):1445-51. doi: 10.1158/1541-7786.MCR-15-0234. Epub 2015 Jul 28. Review.

15.

Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.

Centenera MM, Carter SL, Gillis JL, Marrocco-Tallarigo DL, Grose RH, Tilley WD, Butler LM.

Endocr Relat Cancer. 2015 Oct;22(5):805-18. doi: 10.1530/ERC-14-0541. Epub 2015 Jul 17.

PMID:
26187127
16.

Ex vivo culture of human prostate tissue and drug development.

Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM.

Nat Rev Urol. 2013 Aug;10(8):483-7. doi: 10.1038/nrurol.2013.126. Epub 2013 Jun 11. Review.

PMID:
23752995
17.

Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.

Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, Hsieh JT, Ahn JM, Raj GV.

Nat Commun. 2013;4:1923. doi: 10.1038/ncomms2912.

PMID:
23715282
18.

Targeting cell cycle and hormone receptor pathways in cancer.

Comstock CE, Augello MA, Goodwin JF, de Leeuw R, Schiewer MJ, Ostrander WF Jr, Burkhart RA, McClendon AK, McCue PA, Trabulsi EJ, Lallas CD, Gomella LG, Centenera MM, Brody JR, Butler LM, Tilley WD, Knudsen KE.

Oncogene. 2013 Nov 28;32(48):5481-91. doi: 10.1038/onc.2013.83. Epub 2013 May 27.

19.

Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Gillis JL, Selth LA, Centenera MM, Townley SL, Sun S, Plymate SR, Tilley WD, Butler LM.

Oncotarget. 2013 May;4(5):691-704.

20.

Hsp90: still a viable target in prostate cancer.

Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM.

Biochim Biophys Acta. 2013 Apr;1835(2):211-8. doi: 10.1016/j.bbcan.2012.12.005. Epub 2012 Dec 31. Review.

PMID:
23287571
21.

Dual roles of PARP-1 promote cancer growth and progression.

Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE.

Cancer Discov. 2012 Dec;2(12):1134-49. doi: 10.1158/2159-8290.CD-12-0120. Epub 2012 Sep 19.

22.

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource, Tilley WD, Butler LM.

Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9.

23.

GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells.

Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T.

PLoS One. 2011;6(9):e25634. doi: 10.1371/journal.pone.0025634. Epub 2011 Sep 28.

24.

Finding the place of histone deacetylase inhibitors in prostate cancer therapy.

Marrocco-Tallarigo DL, Centenera MM, Scher HI, Tilley WD, Butler LM.

Expert Rev Clin Pharmacol. 2009 Nov;2(6):619-30. doi: 10.1586/ecp.09.44.

PMID:
22112256
25.

Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Birrell SN, Coetzee GA, Sutherland RL, Butler LM, Tilley WD.

Cancer Res. 2009 Aug 1;69(15):6131-40. doi: 10.1158/0008-5472.CAN-09-0452. Epub 2009 Jul 28.

26.

The contribution of different androgen receptor domains to receptor dimerization and signaling.

Centenera MM, Harris JM, Tilley WD, Butler LM.

Mol Endocrinol. 2008 Nov;22(11):2373-82. doi: 10.1210/me.2008-0017. Epub 2008 Jul 10. Review.

PMID:
18617596
27.

Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant.

Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M, Brown MP, Tilley WD.

Mol Endocrinol. 2006 May;20(5):1009-24. Epub 2006 Jan 19.

PMID:
16423882

Supplemental Content

Loading ...
Support Center